Sign in
Not yet recruitingPhase 1/2

Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study

Key facts

Who runs it
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
12 people, planned
Starts
Jan 2027
Expected to end
Oct 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Injecting KL002 into the bilateral putamen
Record updated
16 November 2026

Who can take part

Age
40 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Clinically diagnosed primary PD
  • Males or females ≥ 40 and ≤ 75 years old
  • History of Parkinson's disease diagnosis ≥ 5 years
  • Regularly take stable equivalent doses of dopaminergic drugs (including levodopa) for at least 4 weeks before the screening period
  • Good compliance and regular follow-up

Who cannot take part

  • Have surgical contraindications or have undergone brain surgery in the past
  • Prior severe allergic reactions or allergic to contrast agents or unable to accept surgical anesthesia
  • Any type of prior gene or cell therapy
  • Atypical or secondary Parkinson's syndrome
  • Any indications of elevated intracranial pressure evaluated by investigator
  • Abnormal liver and kidney function

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Parkinson's disease or advanced primary PD

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.

The 2 groups in the trial

  • low dose groupTreatment being tested

    Putamen stereotactic injection of low dose of KL002

    Treatment: Injecting KL002 into the bilateral putamen

  • high dose groupTreatment being tested

    Putamen stereotactic injection of high dose of KL002

    Treatment: Injecting KL002 into the bilateral putamen

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of KL002 Injection in the Striatal Putamen Region for Patients With Mid-to-Late Stage Primary Parkinson's Disease
Criteria questions
Built from NCT07939295, who can take part
Record updated
16 November 2026